137 patients with acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL) were given oral busulfan (Bu) 4 mg/kg on each of 4 days and intravenous cyclophosphamide (Cy) 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling.
data(leukemia)A data frame with 137 subjects on the following 22 variables.
GDisease Group (1=ALL, 2=AML Low Risk in first remission, 3=AML High Risk not in first remission)
TDTime To Death Or On Study Time
TBDisease Free Survival Time (Time To Relapse, Death Or End Of Study)
DDeath Indicator (0=Alive, 1=Dead)
RRelapse Indicator (0=Disease Free, 1=Relapsed)
BDisease Free Survival Indicator (0=Alive and Disease Free, 1=Dead or Relapsed)
TATime To Acute Graft-Versus-Host Disease (GVHD)
AAcute GVHD Indicator (0=Never Developed Acute GVHD, 1=Developed Acute GVHD)
TCTime To Chronic Graft-Versus-Host Disease (GVHD)
CChronic GVHD Indicator (0=Never Developed Chronic GVHD, 1=Developed Chronic GVHD)
TPTime of Platelets Returning to Normal Levels
PPlatelet Recovery Indicator (0=Platelets Never Returned to Normal, 1=Platelets Returned To Normal)
X1Patient Age In Years
X2Donor Age In Years
X3Patient Gender (0=female, 1=male)
X4Donor Gender (0=female, 1=male)
X5Patient Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X6Donor Cytomegalovirus (CMV) Immune Status (0=CMV Negative, 1=CMV Positive)
X7Waiting Time to Transplant In Days
X8AML Patients with Elevated Risk By French-American-British (FAB) Classification (0=Not AML/Elevated, 1=FAB M4 Or M5 with AML)
X9Hospital (1=The Ohio State University in Columbus, 2=Alfred in Melbourne, 3=St. Vincent in Sydney, 4=Hahnemann University in Philadelphia)
X10Methotrexate Used as a Graft-Versus-Host Disease Prophylactic (0=No, 1=Yes)
Copelan, E.A., Biggs, J.C., Thompson, J.M., Crilley, P., Szer, J., Klein, J.P., Kapoor, N., Avalos, B.R., Cunningham, I. and Atkinson, K. (1991). "Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2". Blood, 78(3), pp.838-843.